2024
Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided
Serve Robotics Inc. ("Serve") (Nasdaq: SERV), a leading autonomous sidewalk
Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in high performance,
Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in high performance, scalable technologies for
Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided
Serve Robotics, Inc.; ("Serve") (Nasdaq: SERV), a leading autonomous sidewalk
Serve Robotics, Inc.. ("Serve") (Nasdaq: SERV), a leading autonomous delivery robotics company, today announced
Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in high performance
Serve Robotics Announces First Quarter 2024
Guerrilla RF, Inc. (OTCQX: GUER) has finalized the
Lumicell, Inc., a privately held company focused on developing innovative
Serve Robotics Inc. (the "Company" or "Serve"), a leading autonomous sidewalk
Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in
Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader
Lumicell Inc., a privately held company focused on
Lumicell, Inc., a privately held company focused on innovative
Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced
Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective technologies for
Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective technologies for
2023
Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides
Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective technologies for
Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides
Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective technologies for
Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective technologies for
Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective technologies for
Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. (NASDAQ: OPK,
Guerrilla RF, Inc. (OTCQX: GUER), a leading provider of state-of-the-art radio frequency and microwave
Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical
Serve Robotics, Inc. (“the Company” or “Serve”), the leading autonomous sidewalk delivery company, today a
Aeluma, Inc. (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective sensor technologies
Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer
Ostendo Technologies, Inc., and Veea Inc. today announced the signing of a letter of intent to combine Ostendo’s
Guerrilla RF, Inc. (OTCQX: GUER), a leading provider of state-of-the-art RF and microwave communications
Aeluma, Inc. (the "Company") (OTCQB:ALMU), a semiconductor company specializing in scalable, cost-effective
2022
Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones:
Aeluma, Inc., announced today that it has named Thomas Laux as Vice President of Business Development.
2021
Virsec Systems, Inc. secures $100 million “show of force” investment as it redefines how software is secured.
Aeluma, Inc. raises $8 million and completes reverse merger.
SmartKem, Inc. Raises $24.6 million and completes reverse acquisition
Angion Biomedica Corp. (NASDAQ: ANGN) announces closing of 117 million initial public offering and concurrent private placement
2020
9 Meters Biopharma, Inc. (NASDAQ: NMTR) announces agreement with the European Biomedical Research Institute of Salerno (EBRIS) to continue evaluation of larazotide for COVID-19 respiratory complications
Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announces completion of enrollment in phase 2 clinical trial of Eb613 In osteoporosis
2019
Peernova, an enterprise blockchain software startup that helps banks and financial institutions simplify reconciliation and other data processes, has raised $31 million in new funding.
Angion Biomedica Corp. (NASDAQ: ANGN) announces several strategic additions to its management team to support the future development and commercialization of ANG-3777
Angion Biomedica Corp. (NASDAQ: ANGN) presents late-breaking data on ANG-377 in delayed graft function at the American Society of Nephrology Kidney Week 2019.
Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) to merge with RDD Pharma creating new gastroenterology company focused on specialty, rare and orphan diseases.
HZO Inc. announced today that it has closed on $70 million in a new financing round.
Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) announced that three abstracts were accepted for presentations during the 2019 Digestive Disease Week (DDW) conference.
Neurotrope, Inc. (NASDAQ: NTRP) announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the research and clinical development of Bryostatin-1.
Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage clinical biopharmaceutical company focused on kidney diseases and other acute organ injuries, announces the recent closing of a $35 million equity private placement.
2018
Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) announced today that Patrick H. Griffin, M.D., F.A.C.P. has joined as the acting head of clinical development.
Angion Biomedica Corp. (NASDAQ: ANGN) and Sinovant Sciences today announced a collaboration and license agreement for BB3, which is shown to have improved renal function post-transplant.
Innovate Biopharmaceuticals, Inc. (“Innovate”) (NASDAQ: INNT) announces it intends to present at the Jefferies 2018 London Healthcare Conference. The conference is being held on November 14-15, 2018.
HZO Inc. announced today that it has acquired Semblant Ltd., a U.K.-based leader in protective nano coatings and waterproof technology.
Innovate Biopharmaceuticals, Inc. (“Innovate”) (NASDAQ: INNT), announced it intends to present at the Ladenburg Thalmann 2018 Healthcare Conference. The conference is being held on October 2, 2018, at the Sofitel Hotel in New York City.
Neurotrope, Inc. (NASDAQ: NTRP), announces that Dr. Charles Ryan, Neurotrope's Chief Executive Officer, will present a company overview at the Ladenburg Thalmann 2018 Healthcare Conference in New York on Tuesday, October 2nd, 2018.
Neurotrope Inc. (NASDAQ: NTRP) is announcing a collaboration with The Nemours / Alfred I. duPont Hospital for Children ("Nemours") to initiate a clinical trial in children with Fragile X Syndrome ("Fragile X").
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) announced today that it has dosed the first patient in the Company’s Phase 1 combination clinical trial of its lead proprietary immuno-oncology drug.
Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) reported its second quarter 2018 financial results and key highlights.
ViewRay, Inc. (NASDAQ: VRAY) today announced the pricing of an underwritten public offering of 16,216,217 shares of common stock.
Neurotrope, Inc. (NASDAQ: NTRP) today provided a business update outlining recent clinical development progress and other noteworthy events that occurred subsequent to the end of the quarter and unaudited financial results for the quarter ended June 30, 2018.
Solbright Group, Inc. (OTC: SBRT) and M2M Spectrum Networks, LLC today announce the signing of a merger agreement creating the first publicly-traded, pure-play, fully-featured IoT network operating company in the U.S., Iota Communications, Inc. (“Iota”).
Innovate Biopharmaceuticals Inc. (NASDAQ: INNT) announced today that it has been added as a member of the broad-market Russell 3000®, 2000® and Microcap® Indexes as part of the 2018 Russell indexes reconstitution.
Innovate Biopharmaceuticals, Inc. (“Innovate”) (NASDAQ: INNT) today announced the appointment of Saira Ramasastry, to its Board of Directors (Board).
Innovate Biopharmaceuticals, Inc. (“Innovate”) (NASDAQ: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for immuno-inflammatory disease, intends to present on larazotide for celiac disease at BIO 2018 in Boston on Tuesday, June 5th.
Neurotrope, Inc. (NASDAQ: NTRP) announces completion of the study design for its confirmatory Phase 2 clinical trial in moderate to severe Alzheimer’s disease.
CALIENT Technologies, Inc., the global leader for optical switching technology, today announced the Edge|640™, a new Optical Circuit Switch (OCS) with 640 fiber-optic cross connections – up to twice the capacity of the company’s market leading S320 OCS.